News

September 6, 2018

Walgreens and Kaléo Partner to Address Epinephrine Auto-Injector Supply Issues, Providing Patients Access to AUVI-Q® (epinephrine injection, USP) Through Walgreens Locations Nationwide
August 29, 2018

AUVI-Q® (epinephrine injection, USP) Available in Canada Starting September 7
August 14, 2018

Kaléo Confirms U.S. Availability of AUVI-Q® (epinephrine injection, USP) Auto-injector for Back-to-School Season
April 26, 2018

With Life-Threatening Allergies Diagnosed in Infancy, Kaléo Announces Availability of First and Only FDA-Approved Epinephrine Auto-Injector (EAI) for Infants and Toddlers Weighing 16.5 to 33 Pounds (7.5 to 15 kilograms)
November 20, 2017

U.S. FDA Approves Kaléo’s AUVI-Q® (Epinephrine Injection, USP) 0.1 mg Auto-Injector for Life-Threatening Allergic Reactions in Infants and Small Children
October 24, 2017

Kaléo Along with National Advocacy Organizations Launch the “No Appetite for Bullying” Initiative
September 1, 2017

Kaléo Donates Thousands of AUVI-Q® (epinephrine injection, USP) and EVZIO® (naloxone HCl injection) Auto-injectors to Hurricane Harvey Relief Efforts
August 7, 2017

Kaléo Announces AUVI-Q® (epinephrine injection, USP) Charitable Donation Program for All Public Elementary Schools in the United States
July 27, 2017

U.S. FDA Grants Priority Review for an Epinephrine Auto-Injector in Development by Kaléo Specifically for Infants and Small Children
January 19, 2017

Kaléo Announces U.S. Availability and Pricing to Patients of Auvi-Q® (Epinephrine Injection, USP) Auto-Injector, For Life-Threatening Allergic Reactions
News Archive